Stem Cell Transplant or Cellular Therapy - Allogeneic

- **Allogeneic**
  - **AML/MDS/ALL**
    - **MDS Only**
      - IRB# 10146: Compares reduced intensity allogeneic stem cell transplant to hypomethylating therapy or best supportive care in patients aged 50-75 with intermediate-2 and high-risk myelodysplastic syndrome.
    - **AML Only**
      - IRB# 17622: Tests the drug Gilteritinib with a placebo for AML with a FLT3/ITD mutation after allogeneic transplant.
    - **IRB# 16189**: Phase 1/phase 2 study of ProTmune ex vivo mobilized peripheral blood cells.
    - **IRB# 18142**: Safety and Efficacy study of ATIR101 Compared to Post-transplant Cyclophosphamide for the prevention of GVHD in a haploidentical transplant (HATCY).
  - **B-Cell Malignancies**
    - **IRB# 19760**: A Phase ½ Study of Allogeneic CRISPR engineered T Cells in patients with B cell malignancy.
  - **Severe Aplastic Anemia**
    - **IRB# 16982**: Donor T-Cell infusion for adults with recurrent minimal residual disease post HSCT.
  - **Multiple Diseases**
    - **IRB# 19907**: BMT CTN 1702 Clinical Transplant Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation.
    - **IRB# 19915**: BMT CTN 1704 Composite Health Assessment Model for Older Adults after Allogeneic Transplant (CHARM).
    - **IRB# 19914**: GRAPHITE Vedolizumab in the Prophylaxis of Intestinal Acute Graft vs Host Disease.
    - **IRB# 19910**: Long Term Follow Up Study to monitor all patients exposed to CD19 directed CAR-T Cells.
    - **IRB# 18301**: Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients.
    - **IRB# 11960**: Long Term Follow Up Study to monitor all patients exposed to CD19 directed CAR-T Cells.

**Key**
- Open for Enrollment
- In Development
- Enrollment on Hold